Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
N GARDINER, M LAWLER… - Leukemia …, 1997 - search.ebscohost.com
Abstract Although Chronic Myeloid Leukaemia (CML) can be treated successfully with
allogeneic bone marrow transplantation (BMT), leukaemia relapse remains a significant
clinical problem. Molecular monitoring of the post transplant marrow can be useful in
predicting relapse particularly in CML patients where the Philadelphia chromosome or its
molecular counterpart, the BCR-ABL fusion messenger RNA can be used as a leukaemia
specific marker of minimal residual disease (MRD). We have investigated chimaerism (using …
allogeneic bone marrow transplantation (BMT), leukaemia relapse remains a significant
clinical problem. Molecular monitoring of the post transplant marrow can be useful in
predicting relapse particularly in CML patients where the Philadelphia chromosome or its
molecular counterpart, the BCR-ABL fusion messenger RNA can be used as a leukaemia
specific marker of minimal residual disease (MRD). We have investigated chimaerism (using …
以上显示的是最相近的搜索结果。 查看全部搜索结果